文献速递炎症性肠病消化道肿瘤与早癌

炎症性肠病中的结肠外恶性肿瘤:来自GETECCU Eneida登记研究的数据

Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.
PubMed 文献 · Am J Gastroenterol · 2017-05-23

该观察性队列研究纳入ENEIDA登记中11011例炎症性肠病患者,中位随访98个月,评估结肠外恶性肿瘤(EC)的患病率、发病率及其与免疫抑制剂和抗肿瘤坏死因子(TNF)药物暴露的关系。EC患病率为3.6%;多因素分析显示年龄(HR=1.05,95%CI=1.04-1.06)和吸烟(HR=1.47,95%CI=1.10-1.80)是与EC风险升高相关的仅有变量;免疫抑制剂和抗TNF药物似乎不增加EC风险。

要点

  • 11011例炎症性肠病患者中结肠外恶性肿瘤患病率为3.6%,中位随访98个月。
  • 年龄(HR=1.05,95%CI=1.04-1.06)和吸烟(HR=1.47,95%CI=1.10-1.80)与EC风险升高相关。
  • 免疫抑制剂和抗TNF药物似乎不增加结肠外恶性肿瘤风险。

核心结论

  • 免疫抑制剂和抗TNF药物似乎不增加结肠外恶性肿瘤风险;年龄较大和吸烟与EC患病率较高相关。

研究设计与样本

  • 观察性队列研究,纳入GETECCU的ENEIDA项目(前瞻性维护的登记)中符合标准的炎症性肠病患者11011例,中位随访98个月。
  • 排除标准为:在炎症性肠病诊断前已有EC、缺乏本研究所需相关数据、既往使用过除糖皮质激素、硫嘌呤类、甲氨蝶呤或抗TNF药物以外的免疫抑制剂。
  • 采用Kaplan-Meier法评估各变量对EC风险的影响,生存曲线差异用log-rank检验评估;采用逐步多因素Cox回归分析随访期间与EC发生相关的因素,包括炎症性肠病治疗药物。

主要发现

  • 48%的患者(5303例)曾暴露于免疫抑制剂或抗TNF药物,45.8%曾暴露于硫嘌呤类,4.7%曾暴露于甲氨蝶呤,21.6%曾暴露于抗TNF药物。
  • 结肠外恶性肿瘤的患病率为3.6%。
  • 多因素分析中,年龄(HR=1.05,95%CI=1.04-1.06)和吸烟(HR=1.47,95%CI=1.10-1.80)是仅有的与EC风险升高相关的变量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was (a) To know the prevalence and distribution of extracolonic cancer (EC) in patients with inflammatory bowel disease (IBD); (b) To estimate the incidence rate of EC; (c) To evaluate the association between EC and treatment with immunosuppressants and anti-tumor necrosis factor (TNF) agents. METHODS: This was an observational cohort study. INCLUSION CRITERIA: IBD and inclusion in the ENEIDA Project (a prospectively maintained registry) from GETECCU. EXCLUSION CRITERIA: Patients with EC before the diagnosis of IBD, lack of relevant data for this study, and previous treatment with immunosuppressants other than corticosteroids, thiopurines, methotrexate, or anti-TNF agents. The Kaplan-Meier method was used to evaluate the impact of several variables on the risk of EC, and any differences between survival curves were evaluated using the log-rank test. Stepwise multivariate Cox regression analysis was used to investigate factors potentially associated with the development of EC, including drugs for the treatment of IBD, during follow-up. RESULTS: A total of 11,011 patients met the inclusion criteria and were followed for a median of 98 months. Forty-eight percent of patients (5,303) had been exposed to immunosuppressants or anti-TNF drugs, 45.8% had been exposed to thiopurines, 4.7% to methotrexate, and 21.6% to anti-TNF drugs. The prevalence of EC was 3.6%. In the multivariate analysis, age (HR=1.05, 95% CI=1.04-1.06) and having smoked (hazards ratio (HR)=1.47, 95% confidence interval (CI)=1.10-1.80) were the only variables associated with a higher risk of EC. CONCLUSIONS: Neither immunosuppressants nor anti-TNF drugs seem to increase the risk of EC. Older age and smoking were associated with a higher prevalence of EC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Chaparro M, Ramas M, Benítez JM, et al. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. Am J Gastroenterol. 2017. PMID: 28534520. doi:10.1038/ajg.2017.96

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。